Published in Br J Dermatol on January 01, 2013
Nonadherence to psoriasis medication as an outcome of limited coping resources and conflicting goals: findings from a qualitative interview study with people with psoriasis. Br J Dermatol (2016) 0.99
Adherence influencing factors - a systematic review of systematic reviews. Arch Public Health (2014) 0.93
'On the surface': a qualitative study of GPs' and patients' perspectives on psoriasis. BMC Fam Pract (2013) 0.90
A Systematic Review of Factors Associated with Non-Adherence to Treatment for Immune-Mediated Inflammatory Diseases. Adv Ther (2015) 0.87
Impact of patient programs on adherence and persistence in inflammatory and immunologic diseases: a meta-analysis. Patient Prefer Adherence (2015) 0.81
Interventions to Improve Adherence in Patients with Immune-Mediated Inflammatory Disorders: A Systematic Review. PLoS One (2015) 0.81
Impact of Treatment-Related Beliefs on Medication Adherence in Immune-Mediated Inflammatory Diseases: Results of the Global ALIGN Study. Adv Ther (2016) 0.80
Supersaturation of Calcipotriene and Betamethasone Dipropionate in a Novel Aerosol Foam Formulation for Topical Treatment of Psoriasis Provides Enhanced Bioavailability of the Active Ingredients. Dermatol Ther (Heidelb) (2016) 0.78
An Applicator Delivery System for Fixed-Combination Calcipotriene Plus Betamethasone Dipropionate Topical Suspension (Gel): Innovating Psoriasis Vulgaris Treatment Through Patient Collaboration. Dermatol Ther (Heidelb) (2015) 0.78
Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systematic review of the literature. Patient Prefer Adherence (2016) 0.78
Nonadherence to Medication Therapy in Haemodialysis Patients: A Systematic Review. PLoS One (2015) 0.77
Frequency of Lost to Follow-Up and Associated Factors for Patients with Rheumatic Diseases. PLoS One (2016) 0.76
The challenges of assessing patients' medication beliefs: a qualitative study. BMC Health Serv Res (2017) 0.75
Adherence to Oral and Topical Medications in Cutaneous Lupus Erythematosus is not Well Characterized. Dermatol Ther (Heidelb) (2015) 0.75
Patient Preferences for Topical Psoriasis Treatments are Diverse and Difficult to Predict. Dermatol Ther (Heidelb) (2016) 0.75
An evolution in switching therapy for psoriasis patients who fail to meet treatment goals. Dermatol Ther (2015) 0.75
Evaluation of 25 years of phototherapy for treating psoriasis at a teaching hospital in southern Spain. An Bras Dermatol (2015) 0.75
Topical medication utilization and health resources consumption in adult patients affected by psoriasis: findings from the analysis of administrative databases of local health units. Clinicoecon Outcomes Res (2017) 0.75
Do English healthcare settings use 'Choice Architecture' principles in promoting healthy lifestyles for people with psoriasis? An observational study. BMC Health Serv Res (2015) 0.75
British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol (2009) 4.12
British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol (2005) 3.10
Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis (2005) 2.61
Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut (2005) 2.36
Effects of a cosmetic 'anti-ageing' product improves photoaged skin [corrected]. Br J Dermatol (2009) 2.25
A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol (2005) 1.72
Response of the hypothalamic-pituitary-adrenal axis to psychological stress in patients with psoriasis. Br J Dermatol (2005) 1.67
Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res (2010) 1.60
Tumour necrosis factor-alpha-induced migration of human Langerhans cells: the influence of ageing. Br J Dermatol (2002) 1.59
A systematic review of motivational interviewing in physical health care settings. Br J Health Psychol (2006) 1.53
The associations of anxiety, depression and personal illness representations with glycaemic control and health-related quality of life in patients with type 2 diabetes mellitus. J Psychosom Res (2004) 1.52
Fumaric acid esters for severe psoriasis: a retrospective review of 58 cases. Br J Dermatol (2005) 1.49
Investigating the role of the HLA-Cw*06 and HLA-DRB1 genes in susceptibility to psoriatic arthritis: comparison with psoriasis and undifferentiated inflammatory arthritis. Ann Rheum Dis (2007) 1.47
Evaluation of an In Silico PBPK Post-Bariatric Surgery Model through Simulating Oral Drug Bioavailability of Atorvastatin and Cyclosporine. CPT Pharmacometrics Syst Pharmacol (2013) 1.44
Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease. J Med Genet (2007) 1.44
Geographical ancestry is a key determinant of epidermal morphology and dermal composition. Br J Dermatol (2014) 1.40
Providing lifestyle behaviour change support for patients with psoriasis: an assessment of the existing training competencies across medical and nursing health professionals. Br J Dermatol (2014) 1.39
Making a 'point' about the safe disposal of sharps in patients on biological therapies. Br J Dermatol (2008) 1.37
A cognitive-behavioural symptom management programme as an adjunct in psoriasis therapy. Br J Dermatol (2002) 1.27
Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol (2013) 1.26
'Not knowing where I am doesn't mean I don't know what I like': cognitive impairment and quality of life responses in elderly people. Int J Geriatr Psychiatry (1999) 1.26
Recognition of need in health care consultations: a qualitative study of people with psoriasis. Br J Dermatol (2012) 1.23
Development of the PSORIQoL, a psoriasis-specific measure of quality of life designed for use in clinical practice and trials. Br J Dermatol (2003) 1.17
Attitudes toward suicide prevention in front-line health staff. Suicide Life Threat Behav (2001) 1.16
A new version of the geriatric depression scale for nursing and residential home populations: the geriatric depression scale (residential) (GDS-12R). Int Psychogeriatr (2000) 1.13
Comprehensive cardiac rehabilitation programme for implantable cardioverter-defibrillator patients: a randomised controlled trial. Heart (2003) 1.13
Environmental risk factors for the development of psoriatic arthritis: results from a case-control study. Ann Rheum Dis (2007) 1.13
Differential contribution of CDKAL1 variants to psoriasis, Crohn's disease and type II diabetes. Genes Immun (2009) 1.12
The role of neuropeptides in psoriasis. Br J Dermatol (2006) 1.12
Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol (2005) 1.11
Adherence to treatment in patients with psoriasis. J Eur Acad Dermatol Venereol (2006) 1.11
Inpatient management of psoriasis: a multicentre service review to establish national admission standards. Br J Dermatol (2007) 1.10
Natural killer and natural killer-T cells in psoriasis. Arch Dermatol Res (2002) 1.09
Predictors of drop-out from an outpatient cardiac rehabilitation programme. Clin Rehabil (2007) 1.09
Interventions for chronic palmoplantar pustulosis. Cochrane Database Syst Rev (2006) 1.09
Striae gravidarum in primiparae. Br J Dermatol (2006) 1.08
Guideline for anti-TNF-alpha therapy in psoriatic arthritis. Rheumatology (Oxford) (2005) 1.05
Detection of psychological distress in patients with psoriasis: low consensus between dermatologist and patient. Br J Dermatol (2004) 1.04
Circulating natural killer cells in psoriasis. Br J Dermatol (2003) 1.04
Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin. Br J Dermatol (2006) 1.04
Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol (2005) 1.03
IL-1beta-induced Langerhans' cell migration and TNF-alpha production in human skin: regulation by lactoferrin. Clin Exp Immunol (2003) 1.03
Management of primary cicatricial alopecias: options for treatment. Br J Dermatol (2008) 1.03
Small-group work and assessment in a PBL curriculum: a qualitative and quantitative evaluation of student perceptions of the process of working in small groups and its assessment. Med Teach (2002) 1.01
The major psoriasis susceptibility locus PSORS1 is not a risk factor for late-onset psoriasis. J Invest Dermatol (2005) 1.00
The diabetes educator: trying hard, but must concentrate more on behaviour. Diabet Med (2006) 1.00
Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol (2011) 1.00
How not to get scar(r)ed: pointers to the correct diagnosis in patients with suspected primary cicatricial alopecia. Br J Dermatol (2009) 0.99
Anti-E-selectin is ineffective in the treatment of psoriasis: a randomized trial. Br J Dermatol (2002) 0.98
A new wrinkle on old skin: the role of elastic fibres in skin ageing. Int J Cosmet Sci (2010) 0.98
A qualitative exploration of multiple medicines beliefs in co-morbid diabetes and cardiovascular disease. Diabet Med (2008) 0.97
Reducing variation in antibacterial prescribing rates for 'cough/cold' and sore throat between 1993 and 2001: regional analyses using the general practice research database. Public Health (2006) 0.97
Genetic susceptibility to psoriasis and psoriatic arthritis: implications for therapy. Br J Dermatol (2012) 0.96
Alcohol consumption and psychological distress in patients with psoriasis. Br J Dermatol (2007) 0.95
The British Association of Dermatologists' Biologic Interventions Register (BADBIR): design, methodology and objectives. Br J Dermatol (2012) 0.95
Costing juvenile idiopathic arthritis: examining patient-based costs during the first year after diagnosis. Rheumatology (Oxford) (2008) 0.95
Clindamycin and rifampicin combination therapy for hidradenitis suppurativa. Br J Dermatol (2006) 0.94
In search of oral psoriasis. Arch Dermatol Res (2011) 0.94
Exploring the association between cardiovascular and other disease-related risk factors in the psoriasis population: the need for increased understanding across the medical community. J Eur Acad Dermatol Venereol (2010) 0.94
Recognition of depression by staff in nursing and residential homes. J Clin Nurs (2000) 0.93
Does psychosocial stress play a role in the exacerbation of psoriasis? Br J Dermatol (2013) 0.93
Systematic review of the analgesic efficacy and tolerability of COX-2 inhibitors in post-operative pain control. J Clin Pharm Ther (2004) 0.92
Interventions for photodamaged skin. Cochrane Database Syst Rev (2005) 0.92
Dependency in older people recently admitted to care homes. Age Ageing (2000) 0.91
Gene expression profiles in psoriasis: analysis of impact of body site location and clinical severity. Br J Dermatol (2005) 0.91
Defining cancer risk in dermatomyositis. Part I. Clin Exp Dermatol (2009) 0.90
The development of personal models of diabetes in the first 2 years after diagnosis: a prospective longitudinal study. Diabet Med (2008) 0.90
Polymorphisms in the PTPN22 region are associated with psoriasis of early onset. Br J Dermatol (2008) 0.90
Evaluation of self-directed clinical education: validation of an instrument. Med Educ (2004) 0.89
Systemic ciclosporin and tacrolimus in dermatology. Dermatol Ther (2007) 0.89
The influence of health threat communication and personality traits on personal models of diabetes in newly diagnosed diabetic patients. Diabet Med (2007) 0.89
Altered claudin expression is a feature of chronic plaque psoriasis. J Pathol (2007) 0.89
A pilot study examining mindfulness-based cognitive therapy in psoriasis. Psychol Health Med (2014) 0.89
Exogenous interleukin-1beta restores impaired Langerhans cell migration in aged skin. Br J Dermatol (2004) 0.89
Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study. J Eur Acad Dermatol Venereol (2009) 0.88
Repair of photoaged dermal matrix by topical application of a cosmetic 'antiageing' product. Br J Dermatol (2007) 0.87
Downregulation and altered spatial pattern of caveolin-1 in chronic plaque psoriasis. Br J Dermatol (2002) 0.87
Lichen planopilaris following hair transplantation and face-lift surgery. Br J Dermatol (2012) 0.87
Lactoferrin: influences on Langerhans cells, epidermal cytokines, and cutaneous inflammation. Biochem Cell Biol (2002) 0.87
The potential of pharmacogenetics in optimizing the use of methotrexate for psoriasis. Br J Dermatol (2005) 0.86
Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Br J Dermatol (2006) 0.86
Successful treatment of psoriasis improves psoriasis-specific but not more general aspects of patients' well-being. Br J Dermatol (2004) 0.86
The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics. J Eur Acad Dermatol Venereol (2009) 0.86
Trade-offs between the benefits and risks of drug treatment for psoriasis: a discrete choice experiment with U.K. dermatologists. Br J Dermatol (2006) 0.85
Naevus sebaceus: a mosaic RASopathy. Clin Exp Dermatol (2014) 0.85
Proteomic analysis of suction blister fluid isolated from human skin. Clin Exp Dermatol (2006) 0.84
The role of beliefs: lessons from a pilot study on illness perception, psychological distress and quality of life in patients with primary cicatricial alopecia. Br J Dermatol (2014) 0.84
A systematic investigation of confirmed autoimmune loci in early-onset psoriasis reveals an association with IL2/IL21. Br J Dermatol (2011) 0.84
Psychological distress in people with disfigurement from facial palsy. Eye (Lond) (2011) 0.84
The care home activity project: does introducing an occupational therapy programme reduce depression in care homes? Aging Ment Health (2007) 0.83
Do selective COX-2 inhibitors increase the risk of cerebrovascular events? A meta-analysis of randomized controlled trials. J Clin Pharm Ther (2006) 0.83
Recent advances in cutaneous angiogenesis. Br J Dermatol (2002) 0.83
A prospective study of systemic sclerosis-related digital ulcers: prevalence, location, and functional impact. Scand J Rheumatol (2013) 0.83
Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms. Br J Dermatol (2008) 0.83
'In someone's clinic but not in mine'--clinicians' views of supporting lifestyle behaviour change in patients with psoriasis: a qualitative interview study. Br J Dermatol (2014) 0.82